On October 17, 2018, Oracle announced that it has signed an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials. The transaction has closed.

Overview

goBalto’s study startup solutions are activated at over 90,000 research sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30% quantifiable reduction in study startup cycle times. Clinical trial site selection and activation is one of the most manual and time consuming process for our customers in the trial design phase and the addition of goBalto will remove another barrier from delivering treatments to patients faster.

Together, Oracle Health Sciences and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.

Upon closing of the transaction, goBalto will be featured as part of Oracle Health Sciences Global Business Unit.

For more information, please visit oracle.com/gobalto.

PRODUCT OVERVIEW AND STRATEGY

What is the rationale for this acquisition?

Oracle Health Sciences already offers customers the industry's most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.

What products and services does goBalto offer?

goBalto is the industry leader in cloud-based study startup software for the global Life Sciences industry, offering the only complete end-to-end platform for starting clinical trials, from site identification, feasibility assessment and selection through to activation, with comprehensive metrics to track adherence to timelines and budget.

How will the proposed acquisition impact the goBalto product roadmap?
Oracle is committed to protecting and enhancing customer investments in goBalto’s solutions. After the close of the transaction, Oracle plans to continue investing in goBalto. We expect this will include more functionality and capabilities at a quicker pace.

**BUSINESS CONTINUITY**

**Can I still purchase goBalto products and services?**
Yes. goBalto products and services continue to be available. Please contact your existing goBalto sales representative to assist you, or visit [www.gobalto.com](http://www.gobalto.com) for contact information.

**Should goBalto customers continue to call goBalto for account management and support?**
Yes. goBalto customers should continue to use existing goBalto contacts for sales and support to address immediate and ongoing needs. We will communicate all changes and transitions occurring well in advance through these familiar channels.

**Should goBalto partners continue to contact goBalto?**
Yes. goBalto partners should continue to use existing goBalto contacts to address immediate and ongoing needs. If contact information changes, we will communicate these changes through normal channels. Oracle partners may also use their existing Oracle channels for support to answer any questions.

**Where can I find out more information about the proposed Oracle and goBalto combination?**
For more information, please visit [oracle.com/gobalto](http://oracle.com/gobalto).
PRODUCT ROADMAP

Oracle is currently reviewing the existing goBalto product roadmap and will be providing guidance to customers in accordance with Oracle’s standard product communication policies. Any resulting features and timing of release of such features as determined by Oracle’s review of goBalto’s product roadmap are at the sole discretion of Oracle. All product roadmap information, whether communicated by goBalto or by Oracle, does not represent a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. It is intended for information purposes only, and may not be incorporated into any contract.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements about Oracle and goBalto, including statements that involve risks and uncertainties concerning Oracle’s proposed acquisition of goBalto, anticipated customer benefits and general business outlook. When used in this document, the words “anticipates”, “can”, “will”, “look forward to”, “expected” and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or goBalto that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this document due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the possibility that the anticipated synergies of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business may deteriorate and/or Oracle or goBalto may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or goBalto. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Neither Oracle nor goBalto is under any duty to update any of the information in this document.

CONNECT WITH US

Call +1.800.ORACLE1 or visit oracle.com. Outside North America, find your local office at oracle.com/contact.

blogs.oracle.com/oracle  facebook.com/oracle  twitter.com/oracle

Integrated Cloud Applications & Platform Services

Copyright © 2018, Oracle and/or its affiliates. All rights reserved. This document is provided for information purposes only, and the contents hereof are subject to change without notice. This document is not warranted to be error-free, nor subject to any other warranties or conditions, whether expressed orally or implied in law, including implied warranties and conditions of merchantability or fitness for a particular purpose. We specifically disclaim any liability with respect to this document, and no contractual obligations are formed either directly or indirectly by this document. This document may not be reproduced or transmitted in any form or by any means, electronic or mechanical, for any purpose, without our prior written permission. Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners. Intel and Intel Xeon are trademarks or registered trademarks of Intel Corporation. All SPARC trademarks are used under license and are trademarks or registered trademarks of SPARC International, Inc. AMD, Opteron, the AMD logo, and the AMD Opteron logo are trademarks or registered trademarks of Advanced Micro Devices. UNIX is a registered trademark of The Open Group. 1118